SBWire

  • Telephone (US) 888-4-SBWire |
  • |
  • Online Support |
  • Contact Us |
  • Customer Login |
  • New Customer? Register

  • Media Relations Solutions
  • Press Room
  • Our Clients
  • Blog
  • Podcasts
  • Support
  • About Us

Find Press Release


Press Room

  • Latest Releases
  • View by Date
  • View by Industry
  • View by Location
  • View by Subject
  • RSS News Feeds
SBWire Spring '08
HostedPR Express

Press Room

Email Press Release Email It! Print Press Release Print It! Word Icon Save It! RSS Feed RSS Feed

Global Market For Blood Disorder Treatments Worth $44.0 Billion By 2012

Posted: Wednesday, June 11, 2008

 

London, UK -- (SBWIRE) -- 06/11/2008 -- Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the global market for blood disorder treatments is expected to increase to nearly $44.0 billion by 2012, experiencing a compound average annual growth rate (CAGR) of 3.7%.

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the global market for blood disorder treatments is expected to increase to nearly $44.0 billion by 2012, experiencing a compound average annual growth rate (CAGR) of 3.7%.

“Blood Disorder Treatments”, which is available at http://www.reportbuyer.com/go/BCC00179 explains that the market is broken down into applications of anemia, hemophilia, neutropenia and thrombosis treatments. Of these, thrombosis treatments have the largest share of the market. Valued at nearly $13.5 billion in 2007, this segment is expected to be worth $16.4 billion by 2012, a CAGR of 4.1%.

Authors of the report say that the second largest segment, anemia treatments, was worth an estimated $12.3 billion in 2007 and will remain steady over the next five years. They predict that continued competitive pressure will result in a stagnant market for this segment, particularly in light of recent generic biologic penetration.

The study finds that the hemophilia treatment market segment will likely display the largest growth during the forecast period due to new product introductions, additional indications, and high demand worldwide. Sales of hemophilia treatments will grow from $6.2 billion in 2007 to $8.8 billion in 2012, reflecting 7.4% growth.

The report also says that growth in the revenues of the Neutropenia market will be driven by Neulasta and Neupogen, both offered by Amgen. This is the smallest segment within the blood disorder market with $4.8 billion in sales for 2007. By 2012,sales will likely reach $6.4 billion, displaying an increase of 6.1%.

“Blood Disorder Treatments” is available from Report Buyer. For more information go to: http://www.reportbuyer.com/pharma_healthcare/treatments/blood_disorder_treatments.html

Report Buyer product ID: BCC00179

About Report Buyer.
Report Buyer is a UK-based independent online store supplying business information. The website now carries over 79,000 business information products, including market reports, studies, books and events. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

Media Relations Contact

Edwin Bailey Email Contact
Report Buyer
+44 (0) 20 7060 7474
http://www.reportbuyer.com

Related Links

Action Web Link Description
Visit Report Buyer's Press Room

Home | Media Relations Solutions | Press Room | Our Clients | Blog | Podcasts | Support | About Us


SBWire - Spring 2008 Release - Copyright © 2005-2008 SBWire - A Division of TEB Media LLC, All Rights Reserved
Important Disclaimer | Security Policy | Terms of Service